Ceftibuten-ledaborbactam
Bacterial infections (novel antibiotic)
Clinical DevelopmentActive (BARDA funded)
Key Facts
Indication
Bacterial infections (novel antibiotic)
Phase
Clinical Development
Status
Active (BARDA funded)
Company
About Basilea Pharmaceutica
Founded in 2000, Basilea Pharmaceutica is a Swiss biopharma company dedicated to addressing the critical global health challenge of antimicrobial resistance. The company has successfully transitioned to a commercial-stage entity with two approved and marketed products, Cresemba and Zevtera, generating revenue and operating profit. With a focused pipeline, strategic collaborations like its BARDA partnership, and a commitment to ESG principles, Basilea is strategically positioned for growth in the specialized anti-infectives market.
View full company profile